Results 361 to 370 of about 3,106,146 (396)

Proteasome inhibitor-induced gastrointestinal toxicity

Current Opinion in Supportive and Palliative Care, 2017
R. Stansborough, R. Gibson
semanticscholar   +1 more source

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Nature Medicine, 2022
Adriaan A Voors, Christiane Angermann Angermann, John R Teerlink   +2 more
exaly  

Proteasome inhibitors

2000
Mohamed A. Iqbal, Mark A. Ator
openaire   +1 more source

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature Medicine, 2021
Barry A Borlaug, Dalane W Kitzman, Sanjiv J Shah   +2 more
exaly  

Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.

American Journal of Health-System Pharmacy, 2015
A. McBride, Jeff Klaus, K. Stockerl-Goldstein   +2 more
semanticscholar   +1 more source

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

Future Oncology, 2015
P. Richardson, P. Moreau, J. Laubach, N. Gupta, A. Hui, K. Anderson, J. S. San Miguel, Shaji K. Kumar   +7 more
semanticscholar   +1 more source

Potent Inhibitors of Proteasome

Journal of Medicinal Chemistry, 1995
M, Iqbal, S, Chatterjee, J C, Kauer, M, Das, P, Messina, B, Freed, W, Biazzo, R, Siman   +7 more
openaire   +2 more sources

Proteasome Inhibitors

2002
openaire   +2 more sources

Proteasome Inhibitors

2021
openaire   +1 more source